  Hereditary leiomyomatosis and renal cell cancer ( HLRCC) is a hereditary cancer syndrome<disease> characterized by inactivation of the Krebs cycle enzyme fumarate hydratase ( FH). HLRCC patients are at high risk of developing kidney cancer of type 2 papillary morphology that is refractory to current radiotherapy , immunotherapy and chemotherapy. Hence , an effective therapy for this deadly form of cancer is urgently needed. Here , we show that FH inactivation ( FH